Imidazole-4-acetic acid hydrochloride
Discontinued ProductImidazole-4-acetic acid hydrochloride (Cat. No. 0815) has been withdrawn from sale for commercial reasons.
Partial GABAc agonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Johnston (1996) GABAc receptors: relatively simple transmitter-gated ion channels? TiPS 17 319 PMID: 8885697
Kusama et al (1993) Pharmacology of GABA r1 and GABA α/β receptors expressed in Xenopus oocytes and COS cells. Br.J.Pharmacol. 109 200 PMID: 8388298
View Related Products by Product Action
Keywords: Imidazole-4-acetic acid hydrochloride, Imidazole-4-acetic acid hydrochloride supplier, I4AA, GABAA-rho, Receptors, 0815, Tocris Bioscience
Citations for Imidazole-4-acetic acid hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Imidazole-4-acetic acid hydrochloride.
Reviews for Imidazole-4-acetic acid hydrochloride
There are currently no reviews for this product. Be the first to review Imidazole-4-acetic acid hydrochloride and earn rewards!
Have you used Imidazole-4-acetic acid hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.